Biology subjects

Auboeuf, D.

Publications and source records attributed to Auboeuf, D..

12 recordsLinked to original sources

bioRxiv2026

The SF3B1 inhibitor pladienolide B massively inhibits DNA damage signaling and repair and counteracts resistance to platinum salts in Non-Small Cell Lung Cancer

BackgroundLung cancer, including Non-Small Cell Lung Carcinoma (NSCLC), is the leading cause of cancer mortality worldwide. Platinum salts are the gold standard chemotherapy for NSCLC but many patients develop resistance leading to disease progression. Identifying new therapeutic strategies to counteract resistance is crucial. Pharmacological compounds targeting core components of the spliceosome machinery have emerged as promising anti-cancer agents. However, their mechanisms of action remain to be elucidated in NSCLC. MethodsVarious NSCLC cell lines were used in 2D and 3D cultures or clonogenic assays. NSCLC Patient-Derived Xenografts were also used. SF3B1 was silenced by siRNA. Flow cytometry was performed to analyze cell cycle distribution and apoptosis. Western-blot, immunofluorescence, SIRF analysis and DNA repair assays were done to assess globally the DNA damage response. RNA-Seq, RT-qPCR and RT-PCR studies were performed to identify gene and splicing events impacted by SF3B1 inhibition. Publicly available transcriptomic and proteomic data were analyzed. ResultsSF3B1 is a core component of the spliceosome machinery. We show that NSCLC cells with acquired resistance to platinum salts are vulnerable to pladienolide B, a SF3B1 inhibitor, or SF3B1 knock-down. Importantly, pladienolide B also slows down tumor growth of NSCLC Patient-Derived Xenografts (PDXs) poorly responsive to platinum salts. Mechanistically, we show that pladienolide B leads to genomic instability and apoptosis, that correlate with early transcription-dependent replication stress and DNA-PKcs activation, followed by the shutdown of ATR/DNA-PKcs-dependent signaling. In addition, pladienolide B profoundly regulates the expression and/or splicing, particularly exon skipping, of numerous genes involved in DNA repair, leading to decreased repair capacities of DNA double strand breaks. Although exon skipping events are mostly transient, skipping of exon 8 of MLH3, a gene involved in mismatch DNA repair, persisted along time. Finally, we show that pladienolide B counteracts resistance to platinum salts in NSCLC cells as well as PDXs, which correlates with enhanced MLH3 exon 8 skipping and decrease of ATR, DNA-PKCs and MLH3 protein levels. ConclusionsAs a whole, our data highlight the targeting of SF3B1 as a potential therapeutic strategy, alone or in combination, in NSCLC patients who escape platinum salts-based chemotherapy.

cancer biology↗

bioRxiv2025

Integrative Analysis of Drug-Gene Expression Signatures in Human Pluripotent Stem Cells Identifies Novel Drug Candidates for ALS and Monogenic Diseases

The classical paradigm of drug screening often faces significant limitations due to the challenges associated with identifying molecular or cellular read-outs that are relevant to specific diseases. This issue is particularly pronounced for the thousands of diseases of genetic origin, given the abundance of databases listing disease-associated changes in gene expression and various transcripts, indicating that potential read-outs may be concealed within these resources. To remedy this, an alternative approach was tested: compounds were evaluated for their effects on gene expression and alternative splicing in a healthy cell model, and the resulting data were matched to molecular signatures of diseases. A subset of 50 FDA-approved drugs was tested on mesenchymal stem cells derived from a human pluripotent stem cell line. Over half of the compounds altered gene expression, many affecting pathways linked to monogenic diseases. One hit, increased SQSTM1 expression induced by prazosin, was further validated in ALS models caused by SQSTM1 haploinsufficiency, including patient-derived fibroblasts, SQSTM1-depleted hiPSC-derived motor neurons, and a zebrafish model. Extending this paradigm could involve testing diverse cell types and larger drug libraries. One Sentence SummaryA novel drug screening approach for monogenic diseases integrating human pluripotent stem cell derivatives and RNA sequencing to profile gene expression.

genomics↗

bioRxiv2024

The MYCN oncoprotein and helicases DDX17 and DDX5 have opposite effects on the production of chimeric transcripts in neuroblastoma cells

DEAD box helicases DDX17 and DDX5 control the termination of transcription and the associated cleavage of the 3 end of transcripts. Here we show that the transcriptional readthrough induced by their depletion in neuroblastoma cells also results in increased production of chimeric transcripts from tandemly oriented genes. Analysis of neuroblastoma tumours in which chimeric transcripts are abundant revealed that low expression of the DDX17 and DDX5 genes is associated with poor overall patient survival. Low DDX17 expression is also significantly associated with high-risk tumours and is inversely correlated with MYCN oncogene amplification, suggesting a link between these two factors. We demonstrate that changes in MYCN expression do not affect the expression of either helicase, but alter transcription termination leading to the production of chimeric transcripts. We provide evidence that MYCN acts on termination through its direct binding to the 3 region of genes and that it interacts with DDX17, suggesting that it may inhibit the activity of the helicase. Collectively, our work reveals a novel function of MYCN in transcription termination and suggests that the deregulation of MYCN and DDX17/DDX5 expression in neuroblastoma may lead to the expression of non-canonical and potentially harmful RNA molecules.

molecular biology↗

bioRxiv2023

Intronic polyadenylation isoforms in the 5' part of genes constitute a source of microproteins and are involved in cell response to cisplatin

Transcript isoforms generated by intronic polyadenylation (IPA) are widely regulated in various biological processes and often encode protein isoforms. Microproteins are small proteins translated from small open reading frames (sORFs) in noncoding RNAs and mRNAs, but their production by IPA isoforms is unknown. Using 3-seq and long-read RNA-seq analyses in lung cancer cells, we show that cisplatin, a DNA-crosslinking anticancer agent, upregulates IPA isoforms relative to full-length mRNAs in long genes. A subset of cisplatin-regulated IPA isoforms are poorly associated with heavy polysomes and terminate upstream of the annotated translation initiation codon of genes. Such IPA isoforms in the PHF20 and PRKAR1B genes are associated with light polysomes, contain Ribo-Seq-supported sORFs in an alternative last exon within the annotated 5UTR part of genes, and are translated into microproteins. For PRKAR1B, the microprotein was detected by Western blot and immunofluorescence after transfection of a tagged isoform; and siRNA depletion of the endogenous IPA isoform, CRISPR deletion of the IPA site, or CRISPR mutation of the sORF initiation codon led to increased cell survival to cisplatin. Based on Ribo-Seq and mass-spectrometry data sets, we identified 156 genes producing both a canonical protein-coding mRNA and a microprotein-coding 5UTR-located IPA isoform (coined miP-5UTR-IPA isoform) regulated by cisplatin. Finally, the regulation of (miP-5UTR-)IPA versus full-length isoforms by cisplatin involved an inhibition of transcription processivity in a FANCD2 and senataxin-dependent manner. Altogether, these findings reveal the novel paradigm of miP-5UTR-IPA genes and their role in cancer cell response to a genotoxic agent. HIGHLIGHTS- Cisplatin increases intronic-polyadenylation versus full-length transcript isoforms in long genes through a FANCD2 and senataxin-dependent decrease of transcription processivity - A subset of cisplatin-regulated intronic-polyadenylation isoforms terminate in the annotated 5UTR part of genes and encode microproteins, thus we coined them miP-5UTR-IPA isoforms - The miP-5UTR-IPA isoform of PRKAR1B impacts cisplatin sensitivity and its effect is mediated by its small ORF - We identify 156 genes producing both a canonical protein-coding mRNA and a microprotein-coding miP-5UTR-IPA transcript

molecular biology↗

bioRxiv2023

MET functions in tumour progression and therapy resistance are repressed by intronic polyadenylation

Intronic polyadenylation (IPA) leads to the production of transcript isoforms with alternative last exons in thousands of mammalian genes. Widespread regulation of IPA isoforms was observed during oncogenic transformation and in tumours versus healthy tissues, and several IPA isoforms were involved in oncogenesis. However, little is known about the potential involvement of IPA in tumour progression, such as cancer cell invasiveness and metastasis, and in resistance to anticancer therapies. Here, we show that an IPA isoform of MET (short MET) whose production is inhibited by U1 snRNP (U1), an essential ribonucleoprotein complex that recognizes the 5 exon-intron junction of pre-mRNA, is associated with better prognosis in breast cancer. Induction of the short MET isoform, using a steric-blocking antisense oligonucleotide targeting the U1 binding site in the vicinity of the short MET alternative polyadenylation site, antagonizes cell invasiveness. U1 blockade with an antisense oligonucleotide targeting the U1 snRNA also decreases breast cancer cell invasiveness, in both human and mouse cancer cell models, and this effect involves IPA induction in MET and several genes belonging to the RAS/RAF/MAPK signalling pathway. Finally, short MET relieves melanoma cell resistance to MAPK cascade-targeted therapy in vitro and in vivo. IPA isoform levels of MET and a few other genes (mTOR, EGFR and CTNNA1) help predict such resistance in patients. Altogether, our findings provide evidence for a role of IPA in both cancer cell invasiveness and resistance to therapy. This suggests that IPA isoforms can be exploited as biomarkers and therapeutic targets to combat tumour progression.

molecular biology↗

bioRxiv2023

Gene-to-Gene Coordinated Regulation of Transcription and Alternative splicing by 3D Chromatin Remodeling upon NF-κB activation

The p65/RelA factor of NF-{kappa}B plays a pivotal role in coordinating gene expression in response to diverse stimuli, including viral infections. At the chromatin level, p65/RelA regulates gene transcription and alternative splicing (AS) through promoter enrichment and genomic exon occupancy, respectively. However, the mechanisms underlying the coordination of these processes across distinct genes remain elusive. In this study, we employed the HTLV-1 Tax oncoprotein, a potent activator of NF-{kappa}B, to investigate the integrative relationship between 3D chromatin architecture, NF-{kappa}B-regulated transcription and AS. Our analysis revealed that Tax induces a pronounced reorganization of the 3D genome, resulting in the formation of multigene complexes that comprise genes regulated either transcriptionally or through AS. Notably, we found that the Tax-induced gene-gene contact between the two master genes NFKBIA and RELA is associated with their differential regulation in gene expression and AS, respectively. Through dCas9-mediated approaches, we demonstrated that NFKBIA-RELA interaction is required for AS regulation and is caused by an intragenic enrichment of p65/RelA on RELA. Our findings shed light on new regulatory mechanisms upon HTLV-1 Tax and underscore the integral role of p65/RelA in coordinated regulation of NF-{kappa}B-responsive genes at both transcriptional and AS levels in the context of the 3D genome.

molecular biology↗

bioRxiv2023

SplicingLore: a web resource for studying the regulation of cassette exons by human splicing factors

One challenge faced by scientists from the alternative RNA splicing field is to decode the cooperative or antagonistic effects of splicing factors to understand and eventually predict splicing outcomes on a genome-wide scale. In this manuscript, we introduce SplicingLore, an open access database and web resource that help to fill this gap in a straightforward manner. The database contains a collection of RNA-seq-derived lists of alternative exons regulated by a total of 75 different splicing factors. All datasets were processed in a standardized manner, ensuring valid comparisons and correlation analyses. The user can easily retrieve a factor-specific set of differentially included exons from the database, or provide a list of exons and search which splicing factor(s) control(s) their inclusion. Our simple workflow is fast and easy to run, and it ensures a reliable calculation of correlation scores between the tested datasets. As a proof of concept, we predicted and experimentally validated a novel functional cooperation between the RNA helicases DDX17 and DDX5 and the HNRNPC protein. SplicingLore is available at https://splicinglore.ens-lyon.fr/.

genomics↗

bioRxiv2023

Metabolism-dependent secondary effect of anti-MAPK cancer therapy on DNA repair

Amino acid bioavailability impacts mRNA translation in a codon depending manner. Here, we report that the anti-cancer MAPK inhibitors (MAPKi) decrease the intracellular concentration of aspartate and glutamate in melanoma cells. This results in the accumulation of ribosomes on codons corresponding to these amino acids and triggers the translation-dependent degradation of mRNAs encoding aspartate- and glutamate-rich proteins mostly involved in DNA metabolism. Consequently, cells that survive to MAPKi degrade aspartate and glutamate to generate energy, which simultaneously decreases their needs in amino acids owing to the downregulation of aspartate- and glutamate-rich proteins involved in cell proliferation. Concomitantly, the downregulation of aspartate- and glutamate-rich proteins involved in DNA repair increases DNA damage loads. Thus, DNA repair defects, and therefore mutations, are, at least in part, a secondary effect of the metabolic adaptation of cells exposed to MAPKi.

cancer biology↗

bioRxiv2020

Translation-dependent and independent mRNA decay occur through mutually exclusive pathways that are defined by ribosome density during T Cell activation.

mRNA translation and degradation are strongly interconnected processes that participate in the fine tuning of gene expression. Particularly, targeting mRNAs to translation-dependent degradation (TDD) could attenuate protein expression by making any increase in mRNA translation self-limiting. However, the extent to which TDD is a general mechanism for limiting protein expression is currently unknown. Here we describe a comprehensive analysis of basal and signal-induced TDD in mouse primary CD4 T cells. Our data indicate that most cellular transcripts are decayed to some extent in a translation-dependent manner, both in resting and activated cells. Our analysis further identifies the length of untranslated regions, the density of ribosomes and the GC content of the coding region as major determinants of TDD magnitude. Consistent with this, all transcripts that undergo changes in ribosome density upon T cell activation display a corresponding change in their TDD level. Surprisingly, the amplitude of translation-independent mRNA decay (TID) appears as a mirror image of TDD. Moreover, TID also responds to changes in ribosome density upon T cell activation but in the opposite direction from the one observed for TDD. Our data demonstrate a strong interconnection between mRNA translation and decay in mammalian cells. Furthermore, they indicate that ribosome density is a major determinant of the pathway by which transcripts are degraded within cells.

genomics↗

bioRxiv2019

Intragenic recruitment of NF-κB drives alternative splicing modifications upon activation by the viral oncogene TAX of HTLV-1.

The chronic NF-{kappa}B activation in inflammation and cancer has long been linked to persistent activation of NF-{kappa}B responsive gene promoters. However, NF-{kappa}B factors such as RELA also massively bind to gene bodies. Here, we demonstrate that the recruitment of RELA to intragenic regions regulates alternative splicing upon activation of NF-{kappa}B by the viral oncogene TAX of HTLV-1. Integrative analysis of RNA splicing and chromatin occupancy, combined with chromatin tethering assays, demonstrate that DNA-bound RELA interacts with and recruits the splicing regulator DDX17 in a NF-kB activation-dependent manner, leading to alternative splicing of target exons thanks to DDX17 RNA helicase activity. This NF-kB/DDX17 axis accounts for a major part of the TAX-induced alternative splicing landscape that mainly affects genes involved in oncogenic pathways. Collectively, our results demonstrate a physical and direct involvement of NF-{kappa}B in alternative splicing regulation, which significantly revisits our knowledge of HTLV-1 pathogenesis and other NF-{kappa}B-related diseases.

molecular biology↗

bioRxiv2019

Interplay between gene nucleotide composition bias and splicing

To characterize the rules governing exon recognition during splicing, we analysed dozens of RNA-seq datasets and identified ~3,200 GC-rich exons and ~4,000 AT-rich exons whose inclusion depends on different sets of splicing factors. We show that GC-rich exons have predicted RNA secondary structures at 5-ss, and are dependent on U1 snRNP-associated proteins. In contrast, AT-rich exons have a large number of branchpoints and SF1-or U2AF2-binding sites and are dependent on U2 snRNP-associated proteins. Nucleotide composition bias also influences local chromatin organization, with consequences for exon recognition during splicing. As the GC content of exons correlates with that of their hosting genes, isochores and topologically-associated domains, we propose that regional nucleotide composition bias leaves a local footprint at the exon level and induces constraints during splicing that can be alleviated by local chromatin organization and recruitment of specific splicing factors. Therefore, nucleotide composition bias establishes a direct link between genome organization and local regulatory processes, like alternative splicing.

molecular biology↗

bioRxiv2018

Interplay between coding and exonic splicing regulatory sequences

The inclusion of exons during the splicing process depends on the binding of splicing factors to short low-complexity regulatory sequences. The relationship between exonic splicing regulatory sequences and coding sequences is still poorly understood. We demonstrate that exons that are coregulated by any splicing factor share a similar nucleotide composition bias. We next demonstrate that coregulated exons preferentially code for amino acids with similar physicochemical properties because of the non-randomness properties of the genetic code. Indeed, amino acids sharing physicochemical properties correspond to codons that have the same nucleotide composition bias. These observations reveal an unanticipated bidirectional interplay between the physicochemical features encoded by exons and exon splicing regulation by splicing factors. We propose that the splicing regulation of an exon by a splicing factor is tightly interconnected with the physicochemical properties of the exon-encoded protein domain depending on the splicing-factor affinity for specific nucleotides.

genomics↗